Targeted biomarker studies are needed to clarify whether MMP-9 is a modifiable mediator of ADT’s tissue remodeling effects—especially in prostate cancer progression, vascular injury, and cardiac remodeling. This evidence concerns the gene MMP9 and prostate cancer.